VIRBAC overview

KEY FIGURES Revenue 1 st quarter 2024 € 345.7 M Growth at constant exchange rates and scope 1 +9.7% of which companion animals +16.2% farm animals +1.2% Growth at constant exchange rates +10.8% Overall change +9.8% 1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights March, 31 2024 8 458 000 Gross total of voting rights : 12 780 944...

KEY FIGURES Annual Revenue 2023 €1,246.9 million Growth at constant exchange rates and scope 1 +4.9% of which companion animals +3.5% farm animals +6.7% Growth at constant exchange rates +4.9% Overall change +2.5% 1 growth at constant exchange rates and scope corresponds to organic growth of revenue, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights December, 31 2023 8 458 000 Gross total of voting rights : 12 775 248...

Press release issued on December 19, 2023 before financial market opening at 8:30am CET Given the strong rebound in revenue observed in the third quarter and continuing into the fourth quarter, a higher-than-expected margin on production costs, and the confirmed postponement of certain expenses, in particular R&D (increase in the ratio of R&D expenses to revenue of only ~+0.5 points compared with 2022), 2023 revenue growth at constant exchange rates and scope is now expected around 4%, while the...

On November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. Founded in 2005, as a joint venture between Suguna Group, one of the leading Indian poultry conglomerates, and Lohmann Animal Health, a German poultry vaccines specialist, Globion has developed robust know-how and expertise in the...

Statement of transactions in own shares from 2023-10-23 to 2023-10-27 BNP PARIBAS Aggregated presentation by day and by market Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code) VIRBAC 969500QQ1X5XHG649644 10/23/2023 FR0000031577 260 252.4019 AQEU VIRBAC 969500QQ1X5XHG649644 10/23/2023...